Early Identification of Alzheimer’s Disease Using Medical Imaging: A Review From a Machine Learning Approach Perspective

Alzheimer’s disease (AD) is the leading cause of dementia in aged adults, affecting up to 70% of the dementia patients, and posing a serious public health hazard in the twenty-first century. AD is a progressive, irreversible and neuro-degenerative disease with a long pre-clinical period, affecting brain cells leading to memory loss, misperception, learning problems, and improper decisions. Given its significance, presently no treatment options are available, although disease advancement can be retarded through medication. Unfortunately, AD is diagnosed at a very later stage, after irreversible damages to the brain cells have occurred, when there is no scope to prevent further cognitive decline. The use of non-invasive neuroimaging procedures capable of detecting AD at preliminary stages is crucial for providing treatment retarding disease progression, and has stood as a promising area of research. We conducted a comprehensive assessment of papers employing machine learning to predict AD using neuroimaging data. Most of the studies employed brain images from Alzheimer’s disease neuroimaging initiative (ADNI) dataset, consisting of magnetic resonance image (MRI) and positron emission tomography (PET) images. The most widely used method, the support vector machine (SVM), has a mean accuracy of 75.4 percent, whereas convolutional neural networks(CNN) have a mean accuracy of 78.5 percent. Better classification accuracy has been achieved by combining MRI and PET, rather using single neuroimaging technique. Overall, more complicated models, like deep learning, paired with multimodal and multidimensional data (neuroimaging, cognitive, clinical, behavioral and genetic) produced superlative results. However, promising results have been achieved, still there is a room for performance improvement of the proposed methods, providing assistance to healthcare professionals and clinician

Wavelet Features for Recognition of First Episode of Schizophrenia from MRI Brain Images

Machine learning methods are increasingly used in various fields of medicine, contributing to early diagnosis and better quality of care. These outputs are particularly desirable in case of neuropsychiatric disorders, such as schizophrenia, due to the inherent potential for creating a new gold standard in the diagnosis and differentiation of particular disorders. This paper presents a scheme for automated classification from magnetic resonance images based on multiresolution representation in the wavelet domain. Implementation of the proposed algorithm, utilizing support vector machines classifier, is introduced and tested on a dataset containing 104 patients with first episode schizophrenia and healthy volunteers. Optimal parameters of different phases of the algorithm are sought and the quality of classification is estimated by robust cross validation techniques. Values of accuracy, sensitivity and specificity over 71% are achieved

Alzheimer’s And Parkinson’s Disease Classification Using Deep Learning Based On MRI: A Review

Neurodegenerative disorders present a current challenge for accurate diagnosis and for providing precise prognostic information. Alzheimer’s disease (AD) and Parkinson's disease (PD), may take several years to obtain a definitive diagnosis. Due to the increased aging population in developed countries, neurodegenerative diseases such as AD and PD have become more prevalent and thus new technologies and more accurate tests are needed to improve and accelerate the diagnostic procedure in the early stages of these diseases. Deep learning has shown significant promise in computer-assisted AD and PD diagnosis based on MRI with the widespread use of artificial intelligence in the medical domain. This article analyses and evaluates the effectiveness of existing Deep learning (DL)-based approaches to identify neurological illnesses using MRI data obtained using various modalities, including functional and structural MRI. Several current research issues are identified toward the conclusion, along with several potential future study directions

BrainPrint: A discriminative characterization of brain morphology

We introduce BrainPrint, a compact and discriminative representation of brain morphology. BrainPrint captures shape information of an ensemble of cortical and subcortical structures by solving the eigenvalue problem of the 2D and 3D Laplace–Beltrami operator on triangular (boundary) and tetrahedral (volumetric) meshes. This discriminative characterization enables new ways to study the similarity between brains; the focus can either be on a specific brain structure of interest or on the overall brain similarity. We highlight four applications for BrainPrint in this article: (i) subject identification, (ii) age and sex prediction, (iii) brain asymmetry analysis, and (iv) potential genetic influences on brain morphology. The properties of BrainPrint require the derivation of new algorithms to account for the heterogeneous mix of brain structures with varying discriminative power. We conduct experiments on three datasets, including over 3000 MRI scans from the ADNI database, 436 MRI scans from the OASIS dataset, and 236 MRI scans from the VETSA twin study. All processing steps for obtaining the compact representation are fully automated, making this processing framework particularly attractive for handling large datasets.National Cancer Institute (U.S.) (1K25-CA181632-01)Athinoula A. Martinos Center for Biomedical Imaging (P41-RR014075)Athinoula A. Martinos Center for Biomedical Imaging (P41-EB015896)National Alliance for Medical Image Computing (U.S.) (U54-EB005149)Neuroimaging Analysis Center (U.S.) (P41-EB015902)National Center for Research Resources (U.S.) (U24 RR021382)National Institute of Biomedical Imaging and Bioengineering (U.S.) (5P41EB015896-15)National Institute of Biomedical Imaging and Bioengineering (U.S.) (R01EB006758)National Institute on Aging (AG022381)National Institute on Aging (5R01AG008122-22)National Institute on Aging (AG018344)National Institute on Aging (AG018386)National Center for Complementary and Alternative Medicine (U.S.) (RC1 AT005728-01)National Institute of Neurological Diseases and Stroke (U.S.) (R01 NS052585-01)National Institute of Neurological Diseases and Stroke (U.S.) (1R21NS072652-01)National Institute of Neurological Diseases and Stroke (U.S.) (1R01NS070963)National Institute of Neurological Diseases and Stroke (U.S.) (R01NS083534)National Institutes of Health (U.S.) ((5U01-MH093765

BrainPrint: A discriminative characterization of brain morphology

We introduce BrainPrint, a compact and discriminative representation of brain morphology. BrainPrint captures shape information of an ensemble of cortical and subcortical structures by solving the eigenvalue problem of the 2D and 3D Laplace–Beltrami operator on triangular (boundary) and tetrahedral (volumetric) meshes. This discriminative characterization enables new ways to study the similarity between brains; the focus can either be on a specific brain structure of interest or on the overall brain similarity. We highlight four applications for BrainPrint in this article: (i) subject identification, (ii) age and sex prediction, (iii) brain asymmetry analysis, and (iv) potential genetic influences on brain morphology. The properties of BrainPrint require the derivation of new algorithms to account for the heterogeneous mix of brain structures with varying discriminative power. We conduct experiments on three datasets, including over 3000 MRI scans from the ADNI database, 436 MRI scans from the OASIS dataset, and 236 MRI scans from the VETSA twin study. All processing steps for obtaining the compact representation are fully automated, making this processing framework particularly attractive for handling large datasets.National Cancer Institute (U.S.) (1K25-CA181632-01)Athinoula A. Martinos Center for Biomedical Imaging (P41-RR014075)Athinoula A. Martinos Center for Biomedical Imaging (P41-EB015896)National Alliance for Medical Image Computing (U.S.) (U54-EB005149)Neuroimaging Analysis Center (U.S.) (P41-EB015902)National Center for Research Resources (U.S.) (U24 RR021382)National Institute of Biomedical Imaging and Bioengineering (U.S.) (5P41EB015896-15)National Institute of Biomedical Imaging and Bioengineering (U.S.) (R01EB006758)National Institute on Aging (AG022381)National Institute on Aging (5R01AG008122-22)National Institute on Aging (AG018344)National Institute on Aging (AG018386)National Center for Complementary and Alternative Medicine (U.S.) (RC1 AT005728-01)National Institute of Neurological Diseases and Stroke (U.S.) (R01 NS052585-01)National Institute of Neurological Diseases and Stroke (U.S.) (1R21NS072652-01)National Institute of Neurological Diseases and Stroke (U.S.) (1R01NS070963)National Institute of Neurological Diseases and Stroke (U.S.) (R01NS083534)National Institutes of Health (U.S.) ((5U01-MH093765

DEEP-AD: The deep learning model for diagnostic classification and prognostic prediction of alzheimer's disease

In terms of context, the aim of this dissertation is to aid neuroradiologists in their clinical judgment regarding the early detection of AD by using DL. To that aim, the system design research methodology is suggested in this dissertation for achieving three goals. The first goal is to investigate the DL models that have performed well at identifying patterns associated with AD, as well as the accuracy so far attained, limitations, and gaps. A systematic review of the literature (SLR) revealed a shortage of empirical studies on the early identification of AD through DL. In this regard, thirteen empirical studies were identified and examined. We concluded that three-dimensional (3D) DL models have been generated far less often and that their performance is also inadequate to qualify them for clinical trials. The second goal is to provide the neuroradiologist with the computer-interpretable information they need to analyze neuroimaging biomarkers. Given this context, the next step in this dissertation is to find the optimum DL model to analyze neuroimaging biomarkers. It has been achieved in two steps. In the first step, eight state-of-the-art DL models have been implemented by training from scratch using end-to-end learning (E2EL) for two binary classification tasks (AD vs. CN and AD vs. stable MCI) and compared by utilizing MRI scans from the publicly accessible datasets of neuroimaging biomarkers. Comparative analysis is carried out by utilizing efficiency-effects graphs, comprehensive indicators, and ranking mechanisms. For the training of the AD vs. sMCI task, the EfficientNet-B0 model gets the highest value for the comprehensive indicator and has the fewest parameters. DenseNet264 performed better than the others in terms of evaluation matrices, but since it has the most parameters, it costs more to train. For the AD vs. CN task by DenseNet264, we achieved 100% accuracy for training and 99.56% accuracy for testing. However, the classification accuracy was still only 82.5% for the AD vs. sMCI task. In the second step, fusion of transfer learning (TL) with E2EL is applied to train the EfficientNet-B0 for the AD vs. sMCI task, which achieved 95.29% accuracy for training and 93.10% accuracy for testing. Additionally, we have also implemented EfficientNet-B0 for the multiclass AD vs. CN vs. sMCI classification task with E2EL to be used in ensemble of models and achieved 85.66% training accuracy and 87.38% testing accuracy. To evaluate the model’s robustness, neuroradiologists must validate the implemented model. As a result, the third goal of this dissertation is to create a tool that neuroradiologists may use at their convenience. To achieve this objective, this dissertation proposes a web-based application (DEEP-AD) that has been created by making an ensemble of Efficient-Net B0 and DenseNet 264 (based on the contribution of goal 2). The accuracy of a DEEP-AD prototype has undergone repeated evaluation and improvement. First, we validated 41 subjects of Spanish MRI datasets (acquired from HT Medica, Madrid, Spain), achieving an accuracy of 82.90%, which was later verified by neuroradiologists. The results of these evaluation studies showed the accomplishment of such goals and relevant directions for future research in applied DL for the early detection of AD in clinical settings.En términos de contexto, el objetivo de esta tesis es ayudar a los neurorradiólogos en su juicio clínico sobre la detección precoz de la AD mediante el uso de DL. Para ello, en esta tesis se propone la metodología de investigación de diseño de sistemas para lograr tres objetivos. El segundo objetivo es proporcionar al neurorradiólogo la información interpretable por ordenador que necesita para analizar los biomarcadores de neuroimagen. Dado este contexto, el siguiente paso en esta tesis es encontrar el modelo DL óptimo para analizar biomarcadores de neuroimagen. Esto se ha logrado en dos pasos. En el primer paso, se han implementado ocho modelos DL de última generación mediante entrenamiento desde cero utilizando aprendizaje de extremo a extremo (E2EL) para dos tareas de clasificación binarias (AD vs. CN y AD vs. MCI estable) y se han comparado utilizando escaneos MRI de los conjuntos de datos de biomarcadores de neuroimagen de acceso público. El análisis comparativo se lleva a cabo utilizando gráficos de efecto-eficacia, indicadores exhaustivos y mecanismos de clasificación. Para el entrenamiento de la tarea AD vs. sMCI, el modelo EfficientNet-B0 obtiene el valor más alto para el indicador exhaustivo y tiene el menor número de parámetros. DenseNet264 obtuvo mejores resultados que los demás en términos de matrices de evaluación, pero al ser el que tiene más parámetros, su entrenamiento es más costoso. Para la tarea AD vs. CN de DenseNet264, conseguimos una accuracy del 100% en el entrenamiento y del 99,56% en las pruebas. Sin embargo, la accuracy de la clasificación fue sólo del 82,5% para la tarea AD vs. sMCI. En el segundo paso, se aplica la fusión del aprendizaje por transferencia (TL) con E2EL para entrenar la EfficientNet-B0 para la tarea AD vs. sMCI, que alcanzó una accuracy del 95,29% en el entrenamiento y del 93,10% en las pruebas. Además, también hemos implementado EfficientNet-B0 para la tarea de clasificación multiclase AD vs. CN vs. sMCI con E2EL para su uso en conjuntos de modelos y hemos obtenido una accuracy de entrenamiento del 85,66% y una precisión de prueba del 87,38%. Para evaluar la solidez del modelo, los neurorradiólogos deben validar el modelo implementado. Como resultado, el tercer objetivo de esta disertación es crear una herramienta que los neurorradiólogos puedan utilizar a su conveniencia. Para lograr este objetivo, esta disertación propone una aplicación basada en web (DEEP-AD) que ha sido creada haciendo un ensemble de Efficient-Net B0 y DenseNet 264 (basado en la contribución del objetivo 2). La accuracy del prototipo DEEP-AD ha sido sometida a repetidas evaluaciones y mejoras. En primer lugar, validamos 41 sujetos de conjuntos de datos de MRI españoles (adquiridos de HT Medica, Madrid, España), logrando una accuracy del 82,90%, que posteriormente fue verificada por neurorradiólogos. Los resultados de estos estudios de evaluación mostraron el cumplimiento de dichos objetivos y las direcciones relevantes para futuras investigaciones en DL, aplicada en la detección precoz de la AD en entornos clínicos.Escuela de DoctoradoDoctorado en Tecnologías de la Información y las Telecomunicacione

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

OBJECTIVE: To quantify the regional and global cerebral atrophy rates and assess acceleration rates in healthy controls, subjects with mild cognitive impairment (MCI), and subjects with mild Alzheimer disease (AD). METHODS: Using 0-, 6-, 12-, 18-, 24-, and 36-month MRI scans of controls and subjects with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we calculated volume change of whole brain, hippocampus, and ventricles between all pairs of scans using the boundary shift integral. RESULTS: We found no evidence of acceleration in whole-brain atrophy rates in any group. There was evidence that hippocampal atrophy rates in MCI subjects accelerate by 0.22%/year2 on average (p = 0.037). There was evidence of acceleration in rates of ventricular enlargement in subjects with MCI (p = 0.001) and AD (p < 0.001), with rates estimated to increase by 0.27 mL/year2 (95% confidence interval 0.12, 0.43) and 0.88 mL/year2 (95% confidence interval 0.47, 1.29), respectively. A post hoc analysis suggested that the acceleration of hippocampal loss in MCI subjects was mainly driven by the MCI subjects that were observed to progress to clinical AD within 3 years of baseline, with this group showing hippocampal atrophy rate acceleration of 0.50%/year2 (p = 0.003). CONCLUSIONS: The small acceleration rates suggest a long period of transition to the pathologic losses seen in clinical AD. The acceleration in hippocampal atrophy rates in MCI subjects in the ADNI seems to be driven by those MCI subjects who concurrently progressed to a clinical diagnosis of AD

Recent advancement in Disease Diagnostic using machine learning: Systematic survey of decades, comparisons, and challenges

Computer-aided diagnosis (CAD), a vibrant medical imaging research field, is expanding quickly. Because errors in medical diagnostic systems might lead to seriously misleading medical treatments, major efforts have been made in recent years to improve computer-aided diagnostics applications. The use of machine learning in computer-aided diagnosis is crucial. A simple equation may result in a false indication of items like organs. Therefore, learning from examples is a vital component of pattern recognition. Pattern recognition and machine learning in the biomedical area promise to increase the precision of disease detection and diagnosis. They also support the decision-making process's objectivity. Machine learning provides a practical method for creating elegant and autonomous algorithms to analyze high-dimensional and multimodal bio-medical data. This review article examines machine-learning algorithms for detecting diseases, including hepatitis, diabetes, liver disease, dengue fever, and heart disease. It draws attention to the collection of machine learning techniques and algorithms employed in studying conditions and the ensuing decision-making process